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OBJECTIVE—Recent advances in human islet transplantation
are hampered by signiﬁcant graft loss shortly after transplanta-
tion and inability to follow islet fate directly. Both issues were
addressed by utilizing a dual-purpose therapy/imaging small
interfering RNA (siRNA)-nanoparticle probe targeting apoptotic-
related gene caspase-3. We expect that treatment with the probe
would result in signiﬁcantly better survival of transplanted islets,
which could be monitored by in vivo magnetic resonance imaging
(MRI).
RESEARCH DESIGN AND METHODS—We synthesized
a probe consisting of therapeutic (siRNA to human caspase-3)
and imaging (magnetic iron oxide nanoparticles, MN) moieties. In
vitro testing of the probe included serum starvation of the islets
followed by treatment with the probe. Caspase-3 gene silencing
and protein expression were determined by RT-PCR and Western
blot, respectively. In vivo studies included serial MRI of NOD-SCID
mice transplanted with MN-small interfering (si)Caspase-3–labeled
human islets under the left kidney capsule and MN-treated islets
under the right kidney capsule.
RESULTS—Treatment with MN-siCaspase-3 probe resulted in
decrease of mRNA and protein expression in serum-starved islets
compared with controls. In vivo MRI showed that there were
signiﬁcant differences in the relative volume change between
MN-siCaspase-3–treated grafts and MN-labeled grafts. Histology
revealed decreased caspase-3 expression and cell apoptosis in
MN-siCaspase-3–treated grafts compared with the control side.
CONCLUSIONS—Our data show the feasibility of combining
siRNA therapy and in vivo monitoring of transplanted islets in
mice. We observed a protective effect of MN-siCaspase-3 in
treated islets both in vitro and in vivo. This study could
potentially aid in increasing the success of clinical islet trans-
plantation. Diabetes 60:565–571, 2011
T
ype 1 diabetes results from a T-cell–mediated
autoimmune attack on pancreatic b-cells (1),
which leads to a deﬁciency in insulin secretion
and hyperglycemia. Human islet transplantation
following the Edmonton protocol has the great potential
to treat type 1 diabetic patients. The rate of insulin in-
dependence 1 year after islet cell transplantation has sig-
niﬁcantly improved in recent years (60% at 1 year after
transplantation compared with 15% previously) (2). How-
ever, at 5 years of follow-up, only approximately 10% of
transplanted patients maintain insulin independence (3).
The major reason for this limited success is drastic de-
crease (up to 70%) of b-cell mass of the islet grafts during
the ﬁrst several weeks after transplantation (4,5). Multiple
immunological and nonimmunological factors contribute
to early graft loss and include allograft rejection, recur-
rence of autoimmunity, and immunosuppressant toxicity,
to name a few (6). In addition, in the absence of estab-
lished vasculature, lack of nutrients and oxygen supply to
the islets results in severe apoptosis. In fact, elevated
levels of apoptosis have been shown in pancreatic islets
exposed to chronic hyperglycemia immediately after trans-
plantation (7). Therefore, the success of islet transplantation
greatly depends on minimizing apoptotic death of the grafts
during the ﬁrst weeks after transplantation (8).
Gene therapy is one strategy aimed at preventing apo-
ptotic islet loss. One of the gene therapy methods for islet
transplantation is introducing protective genes into pan-
creatic islets (e.g., anti-apoptotic genes, genes promoting
neovascularization, etc.) (9). An alternative strategy is
based on silencing certain genes whose expression is im-
plicated in islet apoptosis. In this study, we investigated
the possibility of caspase-3 inhibition by the RNAi mech-
anism. Caspases are a family of proteases that mediate cell
death and are important to the process of cell apoptosis.
Caspase-3 is one of the critical downstream effectors that
mediate cell apoptosis by both the extrinsic and intrinsic
signals pathways (10). Some showed that adenoviral vec-
tors encoding siRNA, targeting the caspase-3 gene, could
inhibit apoptosis in insulinoma cells and human islets (11).
Regardless of the speciﬁc strategies to minimize b-cell
death after transplantation, there is a critical need for islet
monitoring using reliable noninvasive methods. In our
previous studies, we demonstrated that transplanted pan-
creatic islets could be followed over time by magnetic
resonance imaging (MRI) provided that they were labeled
with a suitable contrast agent. Magnetic iron oxide nano-
particles (MN) serve as an excellent contrast agent for
monitoring transplanted islets in rodents (12–15) and in
nonhuman primates (16). As proof of concept, we showed
that small interfering RNA (siRNA) tagged to magnetic
nanoparticles could accumulate in pancreatic islets in
quantities sufﬁcient for detection by MRI in vitro and for
silencing target genes (green ﬂuorescent protein [GFP]
was used as a model gene) (17). In our current study, we
used a dual-purpose therapy/imaging nanoparticle probe
to target the caspase-3 gene. We reason that our “two-in-
one” MN-siCaspase-3-imaging probe would silence the
apoptotic-related gene, providing signiﬁcant protection to
the grafts from the early loss after transplantation, and at
the same time serve as an MRI label to assess the in vivo
post-transplant fate of the grafts noninvasively. Our results
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ORIGINAL ARTICLEindicated that human islets labeled with the probe showed
superior survival after transplantation in mice compared
with the islets labeled with parental probe, as demon-
strated by in vivo MRI during the initial 2-week period
when islet destruction is the most prominent. We believe
that these results provide the groundwork for future
studies, in which dual-purpose probes could target multi-
ple genes implicated in early graft loss (allo-rejection, islet
cell death, autoimmune attack, etc.) with the added beneﬁt
of monitoring the (improved) graft outcome.
RESEARCH DESIGN AND METHODS
siRNA. The double-stranded siRNAs targeting human caspase-3 (GenBank
accession numbers NM_004346, NM_032991) and scrambled siRNA were
designed and synthesized by Dharmacon (Lafatette, CO). The siRNA was
modiﬁed to incorporate a thiol group on the 59 end of the sense strand. There
was no modiﬁcation of the antisense strand.
Probe synthesis and characterization. The probe consisted of magnetic
nanoparticles (for MRI, synthesized as described in Ref. 20) conjugated to
the near-infrared (NIRF) Cy5.5 dye (for correlative microscopy) and to siRNA
(for gene silencing) (Fig. 1A). The synthesis of the probe involved four distinct
steps: synthesis of dextran-coated magnetic nanoparticles (MN), conjugation
of the ﬂuorescent dye Cy5.5-N-hydroxy succinimide ester to MN, conjugation
of the N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) to MN-Cy5.5, and
conjugation of siRNA to MN through SPDP linker. In brief, a solution of
monoactivated Cy5.5 succinimide ester (Amersham Biosciences, Piscataway,
NJ) in 20 mmol/L sodium citrate and 0.15 mol/L NaCl was allowed to react
with the previously dialyzed immunopure, amino-derivatized dextran-coated
iron oxide (aminated iron oxide, MN-NH2) at pH 8.5, with constant agitation
over a period of 12 h at room temperature. The Cy5.5-labeled aminated iron
oxide (MN-NIRF) was puriﬁed from unreacted dye using a Sephadex G-25,
PD-10 column (Amersham Biosciences). A ratio of 2 Cy5.5 molecules per
nanoparticle was obtained. MN-NIRF was then conjugated to the hetero-
bifunctional cross-linker SPDP (Pierce Biotechnology, Rockford, IL) by means
of the N-hydroxy succinimide ester, followed by puriﬁcation using a Sephadex
G-25, PD-10 column in phosphate-buffered saline (PBS)/EDTA, pH 7.5. The
labeling of SPDP per crystal was determined based on the release of pyridine-
2-thione at 343 nm (e = 8.08 3 10
3 M
21cm
21) after the addition of the reducing
agent, tris-(2-carboxyethyl) phosphine hydrochloride (TCEP; 35 mmol/L in
DMSO). A ratio of 31 SPDP molecules per nanoparticle was obtained.
The caspase-3-targeting and scrambled siRNA duplexes were then conju-
gated to MN-Cy5.5-SPDP through its 59-sense thiol group. Before conjugation,
the disulﬁde protecting group on 59-disulﬁde bond was deprotected using
TCEP according to the manufacturer’s instructions. The double-stranded RNA
(dsRNA) was then reacted overnight (4°C) with the previously activated MN-
Cy5.5-SPDP product via the SPDP cross-linker in PBS/EDTA, pH 8, followed
by puriﬁcation using a Quick Spin Column G-50 Sephadex Column (Roche
Applied Science, Indianapolis, IN). The probes designated MN-siCaspase-3/
MN-siSCR (Fig. 1A) were next puriﬁed using magnetic separation columns as
described by the manufacturer (Miltenyi Biotec, Auburn CA). The amount of
conjugated siRNA was assayed using agarose gel electrophoresis. To assess
siRNA dissociation from the nanoparticles under reducing conditions, the
probe was pretreated with 15 mmol/L TCEP for 30 min. The siRNA standard
probes, untreated probes, and probes treated with reducing agents were ap-
plied on a 2% agarose gel in Tris borate-EDTA buffer (Invitrogen, Carlsbad,
CA) at 145 V for 1 h. After electrophoresis, the gel was stained with 0.5 mg/ml
ethidium bromide for 30 min and visualized using a Molecular Imager FX
scanner (Bio-Rad Laboratories, Hercules, CA). The image was quantitated
using the software ImageJ, version 1.43u.
Human islet culture and labeling. Human islets were obtained from the Islet
Cell Resource Centers (National Institutes of Health and Juvenile Diabetes
Research Foundation). The viability and purity of the islets were both higher
FIG. 1. A: Schematic representation of the MN-NIRF-siCaspase-3 probes. B: Agarose gel electrophoresis of MN-near-infrared ﬂuorophore-siCaspase-3
probe. C: Quantitative analysis showed that 105 pmol siRNA was conjugated to MN-NIRF-siCaspase-3 probe. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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(GIBCO, Grand Island, NY) supplemented with 10% FBS and 100 mg/mL
penicillin-streptomycin.
For labeling experiments, 1,000 islet equivalents were counted and in-
cubated for 48 h with either MN-siCaspase-3 or MN-siSCR probe in the same
medium (0.025 mg Fe, 105 pmol siRNA, in 1 mL medium). To mimic the ap-
optotic condition, we cultured a group of islets in CMRL-1066 medium sup-
plemented with 100 mg/mL penicillin-streptomycin without serum (serum
starvation conditions). After incubation, islets were washed three times in
culture medium and used for in vitro and in vivo experiments.
In vitro characterization of labeled islets. Glucose-stimulated insulin se-
cretion was evaluated using static incubation of experimental MN-siCaspase-
and control MN-siSCR–labeled islets at low (1.7 mmol/L) and high (20 mmol/L)
glucose concentrations. Insulin was measured in supernatants and islet
extracts using a human insulin ELISA kit (Mercodia, Uppsala, Sweden). A
stimulation index was calculated as the ratio of stimulated to basal insulin
secretion normalized by the insulin content.
Islet cell viability was determined after labeling by colorimetric (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay according to the
manufacturer’s protocol (Promega, Madison, WI). To determine silencing ef-
fect after islet treatment with the probes, we performed real-time RT-PCR
(TaqMan protocol).
Total RNA was isolated from the experimental and control islets with the
RNeasy Mini kit, according to the manufacturer’s protocol (QIAGEN, Valencia,
CA). The PCR primers and TaqMan probe speciﬁc for caspase-3 were designed
with Primer Express software 1.5. Primer and probe sequences were as fol-
lows: Forward primer, 59-TGTTCCATGAAGGCAGAGCC-39; Reverse primer,
59-TGCGTATGGAGAAATGGGC-39; and TaqMan Probe 59-TGGACCACGCAG-
GAAGGGCCT-39.
Eukaryotic 18S rRNA TaqMan PDAR Endogenous Control reagent mixture
(PE Applied Biosystems, Foster City, CA) was used to amplify 18S rRNA as an
internal control, according to the manufacturer’s protocol. All samples were
run in duplicate.
Caspase-3 protein levels in pancreatic islets were determined by Western
blot with rabbit monoclonal antibody to caspase-3 (Abcam, Cambridge, MA)
followed by horseradish peroxidase-conjugated goat anti-rabbit antibodies
(Cell Signaling Technology, Danvers, MA). Staining of b-actin was used as an
internal control. In situ apoptosis detection was performed using transferase-
mediated dUTP nick-end labeling (TUNEL) assay (Chemicon, Temecula, CA)
according to the manufacturer’s protocol. The percentage of cells undergoing
apoptosis was calculated from the number of nuclei positive for DNA frag-
mentation (ﬂuorescein isothiocyanate [FITC] channel) versus the total number
of cells present (diaminido phenylindol [DAPI] channel).
Microscopy. Fluorescence microscopy of labeled islets was performed with
anticleaved caspase-3 rabbit monoclonal IgG antibody (clone 269518; R&D,
Minneapolis, MN) followed by FITC-labeled anti-rabbit IgG (H+L) secondary
antibody (Vector Laboratories, Burlingame, CA). Slides were mounted with
DAPI-containing mounting medium (Vector Laboratories) and examined un-
der Nikon Eclipse 50i microscope.
For iron staining, we used Prussian Blue stain as described previously (14).
All images were acquired using a CCD camera (SPOT 7.4 Slider RTKE; Di-
agnostic Instruments, Sterling Heights, MI) and analyzed using iVision 4.015
version software.
Islet transplantation. All animal experiments were performed in compliance
with institutional guidelines and approved by the Subcommittee on Research
Animal Care at Massachusetts General Hospital. MN-siCaspase-3–labeled hu-
man pancreatic islets were implanted under the left kidney capsule (1,000 islet
equivalents/kidney) of 6-week-old NOD.scid mice (n = 6). The same number of
islets labeled with parental nanoparticles (MN) was transplanted under the
right kidney capsule of the same animal.
MRI. Islet phantoms were prepared by ﬁxing islet pellets in 2% para-
formaldehyde and sedimenting them in 1% agarose gel. Imaging was performed
using a 9.4T AVANCE scanner (Bruker BioSpin, Billerica, MA) equipped with
ParaVision 3.0.1 software. The imaging protocol consisted of coronal T2
weighted spin echo (SE) pulse sequences with the following parameters:
repetition time (TR)/echo time (TE) = 3,000/8, 16, 24, 32, 40, 48, 56, 64 ms, ﬁeld
of view (FOV) = 3.2 cm
2, matrix size 128, resolution 250 mm
2, and slice
thickness = 0.5 mm. Image reconstruction and analysis were performed using
Marevisi 3.5 software (Institute for Biodiagnostics, National Research Council,
Canada). T2 relaxation times were determined by T2 map analysis of regions
of interest drawn around the islet pellets.
In vivo MRI was performed on a 9.4T scanner 1, 3, 5, 7, and 14 days after
islet transplantation. The imaging protocols consisted of Multi-Slice Multi Echo
T2-weighted map (for volume and T2 relaxivity measurement). Parameters:
FIG. 2. Prussian Blue staining of the islets treated with MN-siCaspase-3 or MN-NIRF probe. A: The islet treated with MN-siCaspase-3 for 48 h.
B: The islet treated with MN-NIRF-siSCR for 48 h. Prussian Blue staining revealed that approximately 95% of islet cells were labeled with the
nanoparticle probes (magniﬁcation bar = 10 mm). C: Fluorescence microscopy shows islets labeled with MN-siCaspase-3 probe (red, Cy5.5; blue,
DAPI nuclear stain). D: Insulin release assay of islets incubated with MN-NIRF-siCaspase-3 or control MN-NIRF-siSCR probe for 48 h. E: Glucose
stimulation index was not signiﬁcantly different in both treatment groups compared with sham-treated islets (P > 0.05). F: MTT assay revealed
that treatment with siRNA-nanoparticle probes does not cause signiﬁcant toxicity to islets (P > 0.05). (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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averages(NA)=4;rapidacquisitionwithrelaxationenhancementfactor=8;FOV=
4.4 cm
2, matrix size 128, spatial resolution 312 mm
2, and slice thickness = 0.5 mm.
We calculated graft volumes by counting the area in each slice of the region of
interest (ROI) outlining the graft and multiplying by the number of slices.
Ex vivo histology. After the last imaging time point, kidneys were removed,
ﬁxed in 4% formaldehyde, and embedded in parafﬁn. Sections were stained for
insulin with anti-human insulin antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) and for caspase-3 with anticleaved caspase-3 rabbit monoclonal IgG
antibody (269518; R&D, Minneapolis, MN). After incubation with Alexa Fluor
594-conjugated secondary goat anti-mouse IgG (H+L; Invitrogen) and FITC-
labeled secondary goat anti-rabbit IgG (Vector Laboratories) and counter-
staining with DAPI, the sections were used for microscopy as described
above. In situ apoptosis detection of kidney sections was performed using
TUNEL assay similar to the procedure described above.
Statistical analysis. Data are presented as means 6 SD. Statistical differ-
ences were analyzed by Student t test (SigmaStat 3.0; Systat Software, Rich-
mond, CA). A value of P , 0.05 was considered statistically signiﬁcant.
RESULTS
Characterization of MN-siCaspase-3 probe. To evalu-
ate the number of siRNA molecules associated with
nanoparticles, we performed gel electrophoresis with MN-
siCaspase-3 under reducing conditions (Fig. 1B). As shown
in Fig. 1C, semiquantitative analysis indicated that 105
pmol siRNA was conjugated to MN-siCaspase-3 probe
containing 25 mg of iron.
The uptake of the probes by human islets was conﬁrmed
by staining for iron with Prussian Blue stain. As shown in
Fig. 2, A and B, approximately 95% of islet cells were la-
beled with MN-siCaspase-3 or MN-SCR probes, which was
conﬁrmed with ﬂuorescence microscopy (Fig. 2C).
At the same time, insulin secretion of human islets fol-
lowing siRNA probe treatment was unaffected in both the
experimental and control groups compared with non-
labeled (sham) islets. Glucose stimulation index was not
signiﬁcantly different in all treatment groups (Fig. 2D and
E; P . 0.05). MTT assay performed on labeled islets
showed that the treatment with the probes did not have
any signiﬁcant effect on islet viability (Fig. 2F; P . 0.05).
To evaluate the protective effect of siRNA probes, we
created treatment conditions where caspase-3 level in the
islets was upregulated. We incubated islets without serum
(serum starvation), treated them with the probes, and
measured caspase-3 mRNA expression by RT-PCR. As
shown in Fig. 3A, caspase-3 mRNA expression was sig-
niﬁcantly reduced by the protective action of the MN-
siCaspase-3 probe. Although the islets treated with MN-siSCR
probes seemed to show a similar trend, the difference
between this treatment and treatment with MN-siCaspase-
3 probe was highly signiﬁcant. It is possible that off-target
effects (18) played a role in this phenomenon. To determine
the caspase-3 protein expression in islets after treatment
with the probes, Western blot of the islet samples was
performed. As shown in Fig. 3B, the expression of caspase-3
protein decreased in islets treated with MN-siCaspase-3
probe compared with control islet group. Fluorescence
microscopy conﬁrmed lower expression of caspase-3 in
serum-starved islets treated with MN-siCaspase-3 probe
compared with the starved nonlabeled islets or islets la-
beled with the control MN-siSCR probe (Fig. 3C). As a con-
sequence, the level of apoptosis in the serum-starved islets
after the treatment with the MN-siCaspase-3 probe was
signiﬁcantly lower than in control islets (Fig. 4A and B).
Together, these results demonstrated that there was a sig-
niﬁcant protective effect of the siRNA probe in islets after
incubation under serum starvation conditions.
Finally, we performed MRI of islet phantoms to prove
that incubation with magnetic nanoparticles leads to islet
labeling, which would allow for following transplanted
islets in vivo. Indeed, labeled islets revealed a signiﬁcant
drop in the T2 relaxation times after incubation with
FIG. 3. A: Real-time semiquantitative RT-PCR of human caspase-3 expression in islets treated with serum starvation and incubated with MN-
siCaspase-3 or the control MN- siSCR probe for 48 h (*n =4 ,P < 0.05 compared with sham control; **n =4 ,P < 0.05 compared with MN-siCaspase-3+SS).
B: Western blot showing decreased level of caspase-3 protein in MN-siCaspase-3–treated islets. C: Fluorescence microscopy conﬁrmed that under
serum starvation condition, the caspase-3 expression in MN-siCaspase-3–treated islets was decreased compared with islets treated with control
probe or serum-starved untreated islets (magniﬁcation bar = 50 mm). (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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unlabeled islets (P , 0.05, Fig. 5A and B).
In vivo MRI of labeled islets. To test our hypothesis
that prelabeling with the magnetic siRNA-nanoparticle
probe would lead to improved protection and better out-
come of islet grafts, we compared the survival properties
of human islet grafts labeled with MN-siCaspase-3 and con-
trol parental nanoparticles (MN) using in vivo MRI. MN-
siCaspase-3–labeled islets were transplanted under the left
kidney capsule, and MN-labeled islets were transplanted
under the right kidney capsule, so each mouse served as
its own control. As shown in Fig. 6A, on T2-weighted MR
images, transplanted islet grafts underneath the renal
capsule appeared as pockets of signal loss disrupting the
contour of both kidneys. ROI analysis performed over time
revealed that the graft volume decreased both in experi-
mental and control groups. However, this decrease was
signiﬁcantly lower in the animals transplanted with MN-
siCaspase-3–labeled islets and was especially pronounced
on days 7 and 14 after transplantation (Fig. 6B, P , 0.05).
These results correlated with ex vivo histology, which
showed reduced expression of caspase-3 in MN-siCaspase-
3–treated grafts (Fig. 6C). On the other hand, insulin ex-
pression was visibly increased in these grafts compared
with controls. This result, in turn, was in accordance with
TUNEL staining, which revealed higher apoptosis levels in
control grafts (Fig. 6D). These data attest to the feasibility
of the MN-siCaspase-3 probe to create a protective effect
for pancreatic islets after transplantation.
DISCUSSION
Islet transplantation can provide type 1 diabetic patients
with improved glycemic control and insulin independence.
However, a substantial proportion of the transplanted islet
mass fails to engraft because of death by apoptosis. A
variety of approaches have been explored to prevent ap-
optotic destruction of islets in the experimental setting.
They include a series of pan-caspase inhibitors and virus
mediated anticaspase gene therapy (10,11). Major con-
cerns regarding these approaches deal with poor selec-
tivity and speciﬁcity of the inhibitors and the safety of viral
vectors. In this study, we demonstrate for the ﬁrst time
that combined siRNA gene therapy and noninvasive im-
aging can create protection for the graft, reduce apoptosis,
and improve the survival properties of the islets in vitro
and in vivo.
Programmed cell death is a cascade of events leading to
the upregulation of the caspase family. Hypoxia, oxidative
damage, serum starvation, inﬂammatory cytokines (tumor
necrosis factor-a, interleukin-1b, g-interferon, etc.), and
other chemical factors (staurosprine, etoposide, cyto-
chrome c, etc.) can induce apoptosis in the islet (19,20).
Here we showed that serum starvation-induced apoptosis
leads to increased caspase activity in the islets. Because
activation of the precursor caspase-3 is the converging
point of apoptosis, we used the MN-siCaspase-3 probe to
label islets to determine whether caspase-3 gene silencing
can block apoptosis induced by serum starvation in vitro.
FIG. 5. A: MR images of islet phantoms revealed a decrease in signal intensity after labeling with either MN or MN-siCaspase-3 compared with
unlabeled (sham) islets. B: T2 relaxation times of islet phantoms. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
FIG. 4. A: TUNEL assay of the islets incubated in the condition of serum
starvation and treated with either MN-siCaspase-3 or MN-siSCR probe
for 48 h (magniﬁcation bar = 50 mm). B: Quantitation of TUNEL assay
reveals signiﬁcantly higher level of apoptosis in serum-starved islets
treated with the control MN-siSCR probe compared with islet treated
with MN-siCaspase-3 probe (*n =4 ,P < 0.05 compared with serum
starvation-treated islets; **n =4 ,P > 0.05 compared with sham-treated
islets). (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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NIRF-siCaspase-3 reduced caspase-3 mRNA transcripts by
50% under serum starvation. Caspase-3 precursor protein
was also signiﬁcantly suppressed as determined by West-
ern blotting 48 h after incubation.
Our in vivo MRI studies showed that the area of the graft
treated with the MN-siCaspase-3 probe was signiﬁcantly
higher than the control islet graft under the renal capsule
7 days and 14 days after transplantation. These data also
demonstrate that during the ﬁrst week after trans-
plantation, there were no differences in reduction of the
graft volume between the control and MN-siCaspase-3
groups. Analysis of T2 maps showed that there was no
signiﬁcant change in T2 relaxation times between MN-
siCaspase-3 and control groups within 2 weeks. This ob-
servation indicated a relative stability of the label within
the graft in both experimental and control kidneys during
the post-transplant period, which was consistent with our
previous report (12).
Because immune rejection could induce apoptosis in the
grafts and interfere with the results, all of the in vivo
experiments were performed in immunocompromised
mice. We propose experiments in diabetic immunocom-
petent mice transplanted with MN-siRNA–labeled pancre-
atic islets in the future.
In summary, our data show the feasibility of two-in-one
combination of siRNA gene protection therapy and in vivo
MRI-noninvasive monitoring of transplanted human islets
in mice. We believe that our dual purposes of nano-
particles in addition to delivering siRNA to pancreatic
islets offer the added beneﬁt of monitoring grafts in early
post-transplant period.
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higher insulin expression in islets treated with MN-siCaspase-3 compared with islets treated with MN on the 14th day post-Tx (red, insulin; green,
TUNEL; blue, DAPI nuclear stain) (magniﬁcation bar = 50 mm). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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